Advertisement
Screener

NewAmsterdam Pharma Company N.V. (NAMS) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

NewAmsterdam Pharma Company N.V. Cash Flow Breakdown

Cash flow breakdown shows where NewAmsterdam Pharma Company N.V.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $147.78M went out.
  • Fiscal year ended 2025-12-31: from investing, $174.92M went out.
  • Fiscal year ended 2025-12-31: from financing, $29.52M came in.
  • Fiscal year ended 2025-12-31: change in cash, $293.18M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingStaff share taxNew shares soldNot split outChange in cash
2025-12-31-$147.78M-$174.92M$29.47M-$293.18M
2024-12-31-$158.56M-$62.85M-$989.00K$1.77M$658.73M*$438.10M
2023-12-31-$141.22M-$24.00K$290.00K$8.62M*-$132.33M
2022-12-31$10.66M-$221.00K$391.90M*$402.35M
2021-12-31-$29.51M-$24.00K$84.70M*$55.17M

Each quarter (3 month)

Quarter endRunning the businessFrom investingStaff share taxNew shares soldNot split outChange in cash
2026-06-30-$39.21M*-$4.76M*$10.89M*
2026-03-31-$30.60M-$11.51M$10.41M$651.00K*-$31.05M
2025-12-31-$40.88M*-$21.14M*$12.50M*$1.18M*
2025-09-30-$32.77M*$2.51M*$5.62M*
2025-06-30-$37.67M*-$159.14M*$3.42M*
2025-03-31-$36.47M$2.85M$7.92M-$1.40M*-$27.09M
2024-12-31-$37.48M*-$62.18M*$0.00*$1.27M*$455.34M*
2024-09-30-$12.50M*-$75.00K*$0.00*$58.00K*
2024-06-30-$53.98M*-$209.00K*$0.00*$0.00*$4.66M*
2024-03-31-$54.60M-$385.00K-$989.00K$440.00K$198.73M*$143.19M
2023-12-31-$33.07M*-$3.00K*$0.00*
2023-09-30-$46.98M*-$9.00K*$185.00K*
2023-06-30-$29.30M*-$5.00K*$6.33M*
2023-03-31-$31.86M-$7.00K$2.39M*-$29.48M

Similar stocks

Stock NameCountryMarket CapPE Ratio
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Immunome Inc. (IMNM)United States$2.538B-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67